Skip to content

Vaginal Microbiota and Post-cesarean SSI

The Relationship Between Vaginal Microbiota and Post-Cesarean Section Wound Infection

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06840041
Enrollment
160
Registered
2025-02-21
Start date
2025-06-30
Completion date
2026-07-30
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section; Complications, Wound, Infection (Following Delivery), Site Infection

Keywords

cesarean section, SSI, vaginal microbiota

Brief summary

The goal of this observational study is to investigate the relationship between vaginal microbiota composition and the development of post-cesarean section wound infection in women undergoing cesarean delivery. The main question it aims to answer is: Is there a correlation between specific vaginal microbiota profiles and the incidence of post-cesarean section wound infection? Can specific bacterial taxa or diversity indices within the vaginal microbiota predict the risk of post-cesarean section wound infection? Participants will: Provide vaginal swab samples pre-operatively and post-operatively. Undergo standard post-cesarean section care and follow-up. Have wound assessment performed per standard of care, and have data collected regarding wound infection status. Have demographic and clinical data collected, including but not limited to, antibiotic use, gestational age, and comorbidities.

Interventions

DIAGNOSTIC_TESTVaginal swab and culture

Participants will undergo vaginal swab collection both pre-operatively, immediately prior to the cesarean section, and post-operatively, within a defined timeframe after the procedure. The swabs will be collected using sterile swabs, following standardized procedures to ensure accurate sampling of the vaginal microbiota. The collected samples will then be sent to a designated laboratory for culture and analysis. This process will identify and characterize the bacterial composition of the vaginal microbiota, allowing researchers to investigate potential correlations between specific microbial profiles and the development of post-cesarean section wound infections

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant women undergoing elective or emergency cesarean section (CS). * Singleton pregnancy. * Cesarean section performed at ≥ 37 weeks of gestation.

Exclusion criteria

* Use of antibiotics within two weeks prior to delivery. * Known immunodeficiency. * Chronic infections. * Ruptured membranes for more than 18 hours.

Design outcomes

Primary

MeasureTime frameDescription
Comparison of Vaginal Microbiota Composition and Surgical Site Infection (SSI) Incidence4 weeks after the surgery.This outcome will assess the differences in vaginal microbiota composition between women who develop a surgical site infection (SSI) following cesarean section and those who do not. Microbiota composition will be determined through culture and analysis of vaginal swab samples collected pre-operatively and post-operatively. Comparisons will focus on identifying significant variations in bacterial taxa, diversity indices, and overall microbial community structure between the two groups.

Secondary

MeasureTime frameDescription
Predictive Value of Specific Vaginal Bacterial Species for Surgical Site Infection (SSI).6 monthsThis outcome will evaluate the ability of specific bacterial species identified in vaginal swab samples to predict the development of surgical site infection (SSI) following cesarean section. Logistic regression analysis will be used to determine the independent predictive value of individual bacterial species, as well as combinations of species, for SSI. The analysis will assess the odds ratios, confidence intervals, and p-values associated with each bacterial species.

Countries

Egypt

Contacts

Primary ContactMuhamed Alhagrasy, M.D.
MuhamedAhmed.216@azhar.edu.eg01017313413

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026